STRATEC SE

Earnings Release • Mar 1, 2007

News Details

Ad-hoc | 1 March 2007 10:56

STRATEC posts record earnings for 2006 financial year

STRATEC Biomedical Systems AG / Preliminary Results

Release of an Ad hoc announcement according to § 15 WpHG, transmitted by
DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

---

STRATEC posts record earnings for 2006 financial year

• Consolidated net income rises by 77.1% to EUR 7.817 million
• Sales increase by 44.6% to EUR 68.414 million
• Substantial rise in EBT margin from 14.6% to 15.9%

Birkenfeld, March 1, 2007

The Board of Management of STRATEC Biomedical Systems AG, which is listed
in the Prime Standard, hereby announces the preliminary unaudited
consolidated results for the 2006 financial year pursuant to IFRS
(International Financial Reporting Standards) and in line with Section 15
of the German Securities Trading Act (WpHG).

Key Figures in EUR 000s 2006 2005 Change
Sales 68,414 47,297 + 44.6%
Gross performance 69,233 48,415 + 43.0%
EBITDA 12,731 8,278 + 53.8%
EBIT 10,915 7,245 + 50.7%
EBT 10,869 6,901 + 57.5%
Consolidated net income 7,817 4,413 + 77.1%
Earnings per share (EUR) 0.70 0.43 + 62.8%

Including Sanguin, which was taken over in 2006, and the employees
transferred from a human resources service provider, the STRATEC Group had
a total of 246 employees as of December 31, 2006 (previous year: 196).

---

Information and Explaination of the Issuer to this News:

The company growth is attributable to the expansion in the number of
appliances sold from among newly launched or already established fully
automated analyzer system families. In 2006, the STRATEC Group supplied a
total of 1,837 analyzer systems to its customers (previous year: 1,175).

The preliminary unaudited consolidated results of the STRATEC Group for the
2006 financial year, with sales of EUR 68.4 million and earnings before tax
(EBT) of Euro 10.9 million, are above the Group’s own expectations. The
company expected to be able to generate sales of EUR 65.0 million to EUR
68.0 million (sales corridor) and earnings before tax (EBT) of EUR 10.5
million to EUR 11.0 million (earnings corridor).

Furthermore, in respect of the 2007 financial year the company expects to
be able to generate sales of EUR 75.0 million to EUR 78.0 million (sales
corridor) and earnings before tax (EBT) of EUR 14.0 million to EUR 15.0
million (earnings corridor). Following this, on the basis of the budget
figures for the 2007 financial year the company expects to be able to
achieve an annual average growth rate of at least 11% in the case of sales
and of at least 16% in the case of earnings before tax (EBT) in the
financial years from 2008 up to and including 2010.

The calculation of the key figure 'earnings per share' for the 2006
financial year is based on a weighted number of shares amounting to
11,104,989. In view of the capital increase undertaken from company funds
in July 2006 (bonus shares, gratis shares), the 'earnings per share' key
figure for the 2005 financial year has been adjusted in the interests of
improved comparability.

The definitive figures for the 2006 financial year will be presented and
commented on in the Annual Results Press Conference Call to be held on
April 4, 2007. Press representatives, investors and analysts wishing to
take part in this telephone conference are kindly requested to register
with our Investor Relations team (Tel: +49 (0)7082 7916-190).

The 2006 Annual Report will be available for downloading from our website
with effect from April 4, 2007.

The Board of Management and Supervisory Board will discuss the distribution
of a dividend, among other matters, at the meeting of the Supervisory Board
held to adopt the financial statements, which is expected to take place on
March 26, 2007.

Our Annual General Meeting for the 2006 financial year will be held in
Pforzheim on May 16, 2007.

About STRATEC

STRATEC Biomedical Systems AG (http://www.stratec-biomedical.de) designs
and manufactures fully automated systems for its partners in the fields of
clinical diagnostics and biotechnology. These partners market such systems,
in general together with their own reagents, to laboratories and research
institutes around the world. The company develops its products on the basis
of its own patented technologies. Shares in the company (ISIN:
DE0007289001) are traded in the Prime Standard segment of the Frankfurt
Stock Exchange and on other exchanges.

The STRATEC Group comprises the listed holding company 'STRATEC Biomedical
Systems AG', as well as the wholly-owned subsidiaries 'STRATEC NewGen GmbH'
and 'Robion AG'.

Further information can be obtained from:

STRATEC Biomedical Systems AG
André Loy, Investor Relations
Gewerbestrasse 37, 75217 Birkenfeld
Germany
Tel: +49 (0)7082 7916 190
Fax: +49 (0)7082 7916 999
E-mail: ir@stratec-biomedical.de

DGAP 01.03.2007

Language: English
Issuer: STRATEC Biomedical Systems AG
Gewerbestraße 37
75217 Birkenfeld Deutschland
Phone: +49 (0)7082 7916 0
Fax: +49 (0)7082 7916 999
E-mail: info@stratec-biomedical.de
www: www.stratec-biomedical.de
ISIN: DE0007289001
WKN: 728900
Indices:
Listed: Geregelter Markt in Frankfurt (Prime Standard), Stuttgart;
Freiverkehr in Berlin-Bremen, München, Düsseldorf

End of News DGAP News-Service

---